key: cord-0802744-5r1dkwxs
authors: Calvisi, Stefania L.; Ramirez, Giuseppe A.; Scavini, Marina; Da Prat, Valentina; Di Lucca, Giuseppe; Laurenzi, Andrea; Gallina, Gabriele; Cavallo, Ludovica; Borio, Giorgia; Farolfi, Federica; Pascali, Maria; Castellani, Jacopo; Lampasona, Vito; D'Angelo, Armando; Landoni, Giovanni; Ciceri, Fabio; Querini, Patrizia Rovere; Tresoldi, Moreno; Piemonti, Lorenzo
title: Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19()
date: 2021-08-05
journal: Metabolism
DOI: 10.1016/j.metabol.2021.154845
sha: 06ce106baac7087eb84e1371a9f13a75c4d6c6c5
doc_id: 802744
cord_uid: 5r1dkwxs

PURPOSE: Individuals with diabetes/stress hyperglycemia carry an increased risk for adverse clinical outcome in case of SARS-CoV-2 infection. The purpose of this study was to evaluate whether this risk is, at least in part, modulated by an increase of thromboembolic complications. METHODS: We prospectively followed 180 hospitalized patients with confirmed COVID-19 pneumonia admitted to the Internal Medicine Units of San Raffaele Hospital. Data from 11 out of 180 patients were considered incomplete and excluded from the analysis. We analysed inflammation, tissue damage biomarkers, hemostatic parameters, thrombotic events (TEs) and clinical outcome according to the presence of diabetes/stress hyperglycemia. RESULTS: Among 169 patients, 51 (30.2%) had diabetes/stress hyperglycemia. Diabetes/stress hyperglycemia and fasting blood glucose (FBG) were associated with increased inflammation and tissue damage circulating markers, higher D-dimer levels, increased prothrombin time and lower antithrombin III activity. Forty-eight venous and 10 arterial TEs were identified in 49 (29%) patients. Diabetes/stress hyperglycemia (HR 2.71, p = 0.001), fasting blood glucose (HR 4.32, p < 0.001) and glucose variability (HR 1.6, p < 0.009) were all associated with an increased risk of thromboembolic complication. TEs significantly increased the risk for an adverse clinical outcome only in the presence of diabetes/stress hyperglycemia (HR 3.05, p = 0.010) or fasting blood glucose ≥7 mmol/L (HR 3.07, p = 0.015). CONCLUSIONS: Thromboembolism risk is higher among patients with diabetes/stress hyperglycemia and COVID-19 pneumonia and is associated to poor clinical outcome. In case of SARS-Cov-2 infection patients with diabetes/stress hyperglycemia could be considered for a more intensive prophylactic anticoagulation regimen.

Diabetes has been confirmed as one of the most consistent risk factors for severe disease in case of SARS-CoV-2 infection [1, 2] . In fact, the risk of admission to an Intensive Care Unit (ICU) and of in-hospital mortality are increased two to three fold by the presence of diabetes in patients with COVID 19 pneumonia [3] . Different pathophysiological mechanisms were suggested to explain the worse clinical outcome, including hyperglycemia, older age and the presence of comorbidities (i.e., hypertension, obesity, and cardiovascular disease) [4] .

However, because of the syndromic nature of diabetes, additional potential causative factors should be considered, such as the increased susceptibility to hyperinflammation [5] , the diminished immunological function [6] and the prothrombotic state [7] associated with hyperglycemia. We recently investigated whether diabetes or hyperglycemia are linked to a defect in the humoral immune response against SARS-CoV-2 [8, 9] . Our data showed that the antibody response against multiple SARS-CoV-2 antigens in patients with diabetes is superimposable in terms of timing, persistence, classes, titers, and neutralizing activity to that of non-diabetic patients [9, 10] . However, in our cohort of patients with SARS-CoV-2 pneumonia, we also observed a significant correlation between serum D-dimer levels and diabetes/hyperglycaemia, a finding confirmed also by others [11] [12] [13] . Elevated D-dimer levels are a direct consequence of increased fibrin formation and lysis and thus an indicator of increased thrombotic activity, such as disseminated intravascular coagulation (DIC) and thromboembolism [14] . COVID-19 is associated with an increased risk of arterial and venous thrombosis [15] [16] [17] because of a multitude of factors, including systemic inflammation, consecutively hospitalized patients with COVID-19 pneumonia, focusing on TEs which occurred during hospitalization and risk factors associated with these events. Health Organization interim guidance [21, 22] . There was no exclusion criterion. A confirmed infection case was defined as a SARS-CoV-2-positive RT-PCR test from a nasal/throat swab, and/or signs, symptoms and radiological findings suggestive of COVID-19 pneumonia.

Within 48 hours from admission, we recorded demographic information, clinical features and laboratory exams on the day of admission on a dedicated data collection form. Data were recorded until hospital discharge or death, whichever occurred first. Data were cross-checked in blind and verified by data managers and clinicians for accuracy. We also recorded mortality beyond hospital discharge clinic: for patients non attending our dedicated outpatient followup clinic, we checked patient's vital status with either family members or family physician.

The study was approved by the Ethics Committee Ospedale San Raffaele (protocol n 34/int/2020). A standard written informed consent was requested to all patients for their data use. Haemostasis (SISET) [23] and to the interim guidance to recognition and management of coagulopathy in COVID-19 from the International Society on Thrombosis and Hemostasis (ISTH) [24] . A close control of hemostasis parameters and clinical signs and symptoms was methodically pursued. Additional investigations, including CT scan and/or ultrasound, were performed on the basis of clinical suspicion of thromboembolic events: (i) elevated D-dimer levels and/or (ii) presence of respiratory failure and/or (iii) presence of symptoms suggestive of TEs. All patients received thromboprophylaxis with enoxaparin 4,000 IU/day [adjusted to 6,000 IU/day or 3,000 IU/day in overweight (>100 kg) or underweight (<50kg) subjects, respectively] or, alternatively, with mechanical compression of the lower limbs in case of anticoagulant contraindications (active bleeding and platelet count less than 25 × 109/l). If chronic oral anticoagulant therapy with direct oral anticoagulants (DOACs) or warfarin/acenocoumarol (oral anticoagulant therapy, OAT) was prescribed prior to admission, it was changed to low-molecular-weight heparin (LMWH) anticoagulant treatment. Recombinant Receptor-Binding-Domain (RBD), recombinant spike protein ectodomain (S1+S2) and nucleoprotein (NP] were tested in a subset of patients by a luciferase immunoprecipitation system (LIPS) assay, as previously described [8] . Fibrinogen, antithrombin activity, von Willebrand factor (VWF), homocysteine, protein C and S. D-dimer levels were measured in a subset of patients through a STA-R® automatic coagulation analyser. Age-specific high D-dimer (aD-dimer) was defined as D-dimer levels above 0.5 µg/dl for patients with less than 50 years of age and above their age divided by 100 in patients older than 50 years [26] .

variables and diabetes was assessed by logistic regression. The effect estimates were reported as Odd Ratios (ORs). Survival was estimated according to Kaplan-Meier. The time-to-event was calculated from the date of symptom onset to the date of the event, or of last follow-up visit, whichever occurred first. We calculated univariate and multivariate Cox proportional hazards models to study the association between patient characteristics with time to thrombotic complication or time to adverse outcome (as defined by composite endpoint of transfer to ICU or death, whichever occurred first). In Cox proportional hazards models, the Table 1 and Table 2 IgG, IgM and IgA responses to the SARS-CoV-2 spike protein (RBD or S1+S2) and IgG to NP (Table 3) were available for a subgroup of patients, as they were part of a previous cohort evaluated for the humoral response in the presence of diabetes (12) . Marginal differences between patients with and without diabetes/stress hyperglycemia were evident. Over the hospitalization period antibiotic (80.4% vs 61.9%, p=0.020) and oxygen (84.3% vs 61%, p=0.004) treatments were more frequently used in patients with diabetes/stress hyperglycaemia while antiviral, immunomodulatory, steroid and biologic therapies were equally prescribed. (Table 3) . Concordantly, the percentage of patients with elevated age-specific D-dimer was significantly higher in the presence of diabetes/stress hyperglycemia (76.5% vs 56.8%, p=0.016). Partial thromboplastin time, platelet count and fibrinogen were not affected by diabetes/stress hyperglycemia.

Advanced markers of thrombophilia were available for a subgroup of patients (Table 3) .

Exploratory analysis did not show significant changes in coagulation factors levels or activity in subjects with diabetes, except for a lower antithrombin III activity [91% (80-120) vs 100% (Table 4 ). The median time from the onset of symptoms of COVID-19 pneumonia to the TE was 17 (10-24) days. Patients with diabetes/stress hyperglycaemia developed more frequently a thromboembolic complication (47.1% vs 21.2%, p=0.001) than patients without diabetes/stress hyperglycaemia. Concordantly, the higher prevalence of thromboembolic complication was associated with higher fasting blood glucose levels during the hospitalization (Table 4 ). Regarding the thrombosis site, venous events (in particular deep vein thrombosis) contributed more significantly than arterial ones to the higher prevalence of thromboembolic complications in patients with diabetes/stress hyperglycaemia compared to those without diabetes/stress hyperglycaemia. In patients with and without diabetes/stress hyperglycaemia, 3 and 1 (5.9% vs 0.8%, p=0.083) events were classified as overt DIC (≥5 points, according to the ISTH diagnostic criteria), respectively. The results of a Cox regression analysis for TE is presented in Figure 1 . was also performed for diabetes and stress hyperglycaemia. Although the number of cases is inadequate for a definitive conclusion, the risk of adverse clinical outcome seems more associated with stress-related hyperglycemia than with diabetes (Figure 3b ).

There are few reports on the relationship between hyperglycemia and the rate of TEs in COVID-19 pneumonia and it is still unknown whether thrombosis affects the prognosis of been taken for granted [27] . TEs have a higher incidence among patients with COVID-19 [28] [29] [30] and diabetes is per se characterized by a pro-thrombotic status [7] . We and others have previously reported an increase of D-dimer in patients with diabetes/stress hyperglycemia and COVID-19 pneumonia compared to those without [11] [12] [13] . However the clinical implications in term of thromboembolic risk of those findings were yet unclear. Moreover, data on the correlation of thromboembolic complications with clinical outcome were limited and contradictory, with some studies finding a higher risk of adverse outcome associated with TEs in hospitalized patients with COVID-19 [31] , while others did not find any association [32] .

The pathophysiological mechanisms related to the increased risk of TEs in patients with COVID-19 pneumonia and diabetes are still incompletely understood. In our study, diabetes/stress hyperglycemia was associated with both inflammation and coagulopathy (elevated C reactive protein and D-dimer levels, mild prolongation of the prothrombin time and decreased antithrombin III), suggesting that an hyperglycaemia-related amplification of the pathobiological mechanisms of immunothrombosis [33] could be responsible of the increased thrombotic risk. The reduced activity of antithrombin III is of particular interest in this context [34] . In fact, antithrombin III is a powerful natural anticoagulant which is J o u r n a l P r e -p r o o f Journal Pre-proof regulated by inflammation [35] . Therefore, it can be speculated that hyperinflammation might have been triggering a decrease in antithrombin III levels and its physiological anticoagulant activity. Furthermore, since the clinical anticoagulant efficacy of heparin requires interaction with antithrombin III, an impaired levels/activity of antithrombin III may be associated with "heparin resistance" [35] . In agreement with this hypothesis, an association between antithrombin III levels and mortality in patients with COVID-19 pneumonia has already been reported [36] . An association between thromboembolic complications and the presence of antiphospholipid antibodies in patients with COVID-19 pneumonia has been previously reported in case reports, case series, cohort studies, and cross-sectional studies, although with contradictory results [37] . Unfortunately antiphospholipid antibody measurements were available only for a subgroup of our patients and, therefore, it was impossible to include them in a multivariate model to test for their contribution to thromboembolic risk.

An interesting result from out study is the fact that thromboembolism events did not happen after 100 days from symptom onset both in diabetes and non-diabetes patients. This supports the idea that thrombotic events are mainly sustained by the acute inflammatory phase of the disease while chronic inflammation or mechanisms possibly related to the activation of autoimmunity, which were suggest to be relevant for the post-acute COVID-19 syndrome, appear less relevant [38] . Of note, while comorbid diabetes and stress hyperglycaemia were both associated with a higher prevalence of thromboembolic complication, the risk of adverse clinical outcome seems more associated with stress-related hyperglycemia than with diabetes.

Although there are not much enough cases for a definitive conclusion, this finding suggests that the new onset hyperglycemia is more dangerous than the established diabetes. Since the mean blood glucose during hospitalization was not different in patients with either new-onset or preexisting diabetes (data not shown), factors other than hyperglycemia should be considered to explain this differences.

Our study encompasses some limitations: first, our cohort was limited to hospitalized patients and results could be different in less severe COVID-19 disease. Second, even if the overall venous and arterial thromboembolism rate was similar to that described until now in various studies [15] , our monocentric cohort was relatively small, and, therefore, a selection bias cannot be excluded. Third, we were unable to evaluate the specific role of some markers as predictors of thrombosis in multivariate models since a complete set of biochemical coagulation data was available only for a fraction of patients. Fourth, a role of a genetic thrombophilia predisposition within our cohort was not assessed. The presence of genetic polymorphisms related to higher risk for inherited thrombophilia did not emerge from any patient's medical history, however, genotyping was not performed during hospitalization and we cannot exclude its presence. However, since the prevalence of genetic thrombophilia susceptibility is not known to be higher in subjects with diabetes, it is very unlikely that it Nevertheless, our study generated additional valuable knowledge about the role of diabetes/stress hyperglycemia in predicting TEs and in stratifying their prognostic significance.

Many evidences indicate that patients with diabetes, in case of COVID-19 pneumonia, carry a significant increased risk for adverse clinical outcome when compared with patients without diabetes. It is clear from our study that part of this excess risk is due to an increase in 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Diabetes is a risk factor for the progression and prognosis of COVID-19

Immune dysfunction in patients with diabetes mellitus (DM)

Diabetes mellitus and thrombosis

COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Relation of D-dimer levels of COVID-19 patients with diabetes mellitus

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care

The current role and future prospects of D-dimer biomarker

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Prognosis of COVID -19 in patients with vein thrombosis: a systematic review and meta-analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Thromboinflammation and the hypercoagulability of COVID-19

Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

The diagnosis and treatment plan for the novel coronavirus disease. The seventh edition 2020

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation

Ageadjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study

Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

COVID-19 and thrombosis: From bench to bedside

Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome

Prevalence of venous thromboembolism in critically ill patients with COVID-19

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms

Understanding the andromeda strain -The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness

Antithrombin: anti-inflammatory properties and clinical applications

Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity

COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association

Postacute COVID-19 syndrome

Data Curation, Investigation, Writing -Review & Editing Giuseppe A Ramirez Data Curation, Investigation, Writing -Review & Editing Marina Scavini: Writing -Review & Editing, Formal analysis Valentina Da Prat: Investigation Giuseppe Di Lucca: Investigation Andrea Laurenzi: Investigation Gabriele Gallina: Investigation Ludovica Cavallo: Investigation Giorgia Borio: Investigation Federica Farolfi: Investigation Maria Pascali: Investigation Jacopo Castellani: Investigation Vito Lampasona: Resources

Writing -Review & Editing Giovanni Landoni: Resources Fabio Ciceri: Funding acquisition

Data Curation J o u r n a l P r e

Formal analysis, Writing -Original Draft